(Unaudited data)
-
CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2017
July 20, 2017
in thousands of euros
2016
2017
Variation at
current exchange rates
Variation at constant exchange rates
France
170,963
176,462
+3.2%
+3.2%
Europe (excluding France)
75,257
67,839
-9.9%
-12.9%
North America
30,177
32,644
+8.2%
+5.1%
Other countries
7,907
7,723
-2.3%
-7.9%
Group total
284,304
284,668
+0.1%
-1.2%
in thousands of euros
2016
2017
Variation at
current exchange rates
Variation at constant exchange rates
Non-proprietary Homeopathic Medicines OTC Specialties
Other
156,148
127,462
694
155,583
128,359
726
-0.4%
+0.7%
+4.6%
-0.6%
-1.9%
+4.3%
Group total
284,304
284,668
+0.1%
-1.2%
- ACTIVITY BY QUARTER(variation at current exchange rates)
1stquarter | 2ndquarter | |||||
in thousands of euros | ||||||
2016 | 2017 | Var. 17/16 | 2016 | 2017 | Var. 17/16 | |
France | 90,494 | 97,134 | +7.3% | 80,469 | 79,328 | -1.4% |
Europe (excluding France) | 43,685 | 40,418 | -7.5% | 31,572 | 27,421 | -13.1% |
North America | 16,064 | 18,179 | +13.2% | 14,113 | 14,465 | +2.5% |
Other countries | 3,846 | 4,532 | +17.8% | 4,061 | 3,191 | -21.4% |
Group total | 154,089 | 160,263 | +4.0% | 130,215 | 124,405 | -4.5% |
1stquarter | 2ndquarter | |||||
in thousands of euros | 2016 | 2017 | Var. 17/16 | 2016 | 2017 | Var. 17/16 |
Non-proprietary Homeopathic Medicines | 80,147 | 81,016 | +1.1% | 76,001 | 74,567 | -1.9% |
OTC Specialties | 73,743 | 78,968 | +7.1% | 53,719 | 49,391 | -8.1% |
Other | 199 | 279 | +40.2% | 495 | 447 | -9.7% |
Group total | 154,089 | 160,263 | +4.0% | 130,215 | 124,405 | -4.5% |
Sales revenue of the second quarter decreased by 4.5% (covering a favorable exchange rate impact of 0.6%) in comparison to the 2016 second quarter. Such decrease was due to a regression of the activity in France and in the other European countries and a progression in North America and Brazil.
Operating income in the first half of 2017 should be lower than the one in 2016.
The implementation of the new organization of the establishments in France has begun in a good climate of consultation with the concerned people and the staff representatives. Six people have refused the proposal to amend their employment contract. The impact on the consolidated half-year financial statements should not be significant.
The acquisition of the land in Les Olmes (area of Lyon) where the future logistic platform of the group shall be located has been concluded on June 10, 2017 for an amount of €2,260 thousand.
In Canada, the Supreme Court rejected the appeal of our Canadian subsidiary against the judgment dated October 26, 2016 of the Quebec Court of Appeal which authorized the start of a class action proceeding. This proceeding continues on the merits before the Superior Court of Quebec. No amount has been accrued to cover this litigation.
Our company carries on the development of homeopathy in the world with the same determination.
Our next update:
September 7, 2017: at market close, publication of 2017 half-year results. Person responsible for financial information: Christian Boiron.
Contact for financial information: Véronique Bouscayrol.
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com
Boiron SA published this content on 20 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 July 2017 11:14:03 UTC.
Public permalinkhttp://www.publicnow.com/view/18170A9145CD2E0E4C241E245A5AB8DCEA088A2E